EJCTS Click here to locate an Ethicon representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hage, R.
Right arrow Articles by van den Bosch, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hage, R.
Right arrow Articles by van den Bosch, J.
Related Collections
Right arrow Lung - cancer

Eur J Cardiothorac Surg 2002;23:457-460
© 2002 Elsevier Science NL


Pulmonary large-cell neuroendocrine carcinoma (LCNEC)

René Hagea, Kees Seldenrijkb, Peter de Bruinb, Henry van Swietenc, Jules van den Boscha*

a Department of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands
b Department of Pathology, St Antonius Hospital, Nieuwegein, The Netherlands
c Department of Thoracic Surgery, St Antonius Hospital, Nieuwegein, The Netherlands

Received 8 October 2002; received in revised form 9 December 2002; accepted 16 December 2002.

* Corresponding author. Tel.: +31-30-6092428; fax: +31-30-6052001
e-mail: j.vandenbosch{at}antonius.net

Objective: The experiences on the treatment of seven consecutive patients with large-cell neuroendocrine carcinoma (LCNEC) were studied, observed over 6 years from 1992. Since LCNEC was recognized as a separate histological entity, only very few series have been reported. Together with the carcinoids (atypical and typical) and the small-cell lung carcinoma (SCLC), it forms the spectrum of neuroendocrine tumors. Methods: Between 1992 and 1997, seven patients who underwent surgical resection were diagnosed as LCNEC postoperatively. Mean age was 65 years (range 54–77 years), five patients were male, all patients were heavy smokers. One patient was staged as IA, four as IB, one as IIIB and one as IV. Results: In five patients, preoperative diagnosis was unknown, in one squamous cell carcinoma and in one adenocarcinoma was suspected. There were four lobectomies, two bilobectomies and one resection of the lingular division with a wedge resection of the upper division of the left upper lobe. Three patients received adjuvant chemotherapy and one, adjuvant radiotherapy. Survival ranged from 7 to 39 months. There are no patients currently alive. Conclusions: LCNEC is a high-grade neuroendocrine tumor with a poor prognosis. In our patients, after surgical resection or multimodality treatment, all have developed widespread metastatic disease with a rapidly fatal course. Due to the rarity of this tumor, the incidence, prognosis and optimal treatment remain to be determined.

Key Words: Large-cell neuroendocrine carcinoma • Large cell • Neuroendocrine • Pulmonary • Carcinoma




This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
A. Iyoda, K. Hiroshima, Y. Nakatani, and T. Fujisawa
Pulmonary Large Cell Neuroendocrine Carcinoma: Its Place in the Spectrum of Pulmonary Carcinoma
Ann. Thorac. Surg., August 1, 2007; 84(2): 702 - 707.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
A. Iyoda, K. Hiroshima, Y. Moriya, Y. Sekine, K. Shibuya, T. Iizasa, Y. Nakatani, and T. Fujisawa
Prognostic impact of large cell neuroendocrine histology in patients with pathologic stage Ia pulmonary non-small cell carcinoma.
J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 312 - 315.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. Rossi, A. Cavazza, A. Marchioni, L. Longo, M. Migaldi, G. Sartori, N. Bigiani, L. Schirosi, C. Casali, U. Morandi, et al.
Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFR{alpha}, PDGFR{beta}, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung
J. Clin. Oncol., December 1, 2005; 23(34): 8774 - 8785.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
R. J. Battafarano, F. G. Fernandez, J. Ritter, B. F. Meyers, T. J. Guthrie, J. D. Cooper, and G. A. Patterson
Large cell neuroendocrine carcinoma: An aggressive form of non-small cell lung cancer
J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 166 - 172.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
P. L. Filosso, E. Ruffini, A. Oliaro, O. Rena, C. Casadio, M. Mancuso, D. Turello, R. C. Cristofori, and G. Maggi
Large-cell neuroendocrine carcinoma of the lung: A clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide
J. Thorac. Cardiovasc. Surg., April 1, 2005; 129(4): 819 - 824.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
P. L. Filosso
Large-cell neuroendocrine carcinoma (LCNC) of the lung: a dilemma
Eur. J. Cardiothorac. Surg., October 1, 2003; 24(4): 672 - 672.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.